Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability
Recent evidences showed the existence of a central nervous system 'waste clearance' system, defined as glymphatic system. Glymphatic abnormalities have been described in several neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Glymphatic function has n...
Saved in:
| Published in: | Brain (London, England : 1878) Vol. 145; no. 8; p. 2785 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
27.08.2022
|
| Subjects: | |
| ISSN: | 1460-2156, 1460-2156 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Recent evidences showed the existence of a central nervous system 'waste clearance' system, defined as glymphatic system. Glymphatic abnormalities have been described in several neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Glymphatic function has not been thoroughly explored in multiple sclerosis, where neurodegenerative processes are intermingled with inflammatory processes. We aimed to investigate glymphatic system function in multiple sclerosis and to evaluate its association with clinical disability, disease course, demyelination and neurodegeneration, quantified using different MRI techniques. In this retrospective study, we enrolled 71 multiple sclerosis patients (49 relapsing-remitting and 22 progressive multiple sclerosis) and 32 age- and sex- matched healthy controls. All subjects underwent neurological and MRI assessment including high-resolution T1, T2 and double inversion recovery sequences, diffusion- and susceptibility weighted imaging. We calculated the diffusion along perivascular space index, a proxy for glymphatic function, cortical and deep gray matter volume, white and cortical gray matter lesion volume and normal appearing white matter microstructural damage. Multiple sclerosis patients showed an overall lower diffusion along perivascular space index vs healthy controls (estimated mean difference: -0.09, P = 0.01). Both relapsing-remitting and progressive multiple sclerosis patients had lower diffusion along perivascular space index vs healthy controls (estimated mean difference: -0.06, P = 0.04 for relapsing-remitting and -0.19, P = 0.001 for progressive multiple sclerosis patients). Progressive multiple sclerosis patients showed lower diffusion along perivascular space index vs relapsing-remitting multiple sclerosis patients (estimated mean difference: -0.09, P = 0.03). In multiple sclerosis patients, lower diffusion along perivascular space index was associated with more severe clinical disability (r = -0.45, P = 0.001) and longer disease duration (r = -0.37, P = 0.002). Interestingly, we detected a negative association between diffusion along perivascular space index and disease duration in the first 4.13 years of the disease course (r = -0.38, P = 0.04) without any association thereafter (up to 34 years of disease duration). Lower diffusion along perivascular space index was associated with higher white (r = -0.36, P = 0.003) and cortical (r = -0.41, P = 0.001) lesion volume, more severe cortical (r = 0.30, P = 0.007) and deep (r = 0.42, P = 0.001) gray matter atrophy, reduced fractional anisotropy (r = 0.42, P = 0.001) and increased mean diffusivity (r = -0.45, P = 0.001) in the normal-appearing white matter. Our results suggest that the glymphatic system is impaired in multiple sclerosis, especially in progressive stages. Impaired glymphatic function was associated with measures of both demyelination and neurodegeneration and reflects a more severe clinical disability. These findings suggest that glymphatic impairment may be a pathological mechanism underpinning multiple sclerosis. The dynamic interplay with other pathological substrates of the disease deserves further investigation. |
|---|---|
| AbstractList | Recent evidences showed the existence of a central nervous system 'waste clearance' system, defined as glymphatic system. Glymphatic abnormalities have been described in several neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Glymphatic function has not been thoroughly explored in multiple sclerosis, where neurodegenerative processes are intermingled with inflammatory processes. We aimed to investigate glymphatic system function in multiple sclerosis and to evaluate its association with clinical disability, disease course, demyelination and neurodegeneration, quantified using different MRI techniques. In this retrospective study, we enrolled 71 multiple sclerosis patients (49 relapsing-remitting and 22 progressive multiple sclerosis) and 32 age- and sex- matched healthy controls. All subjects underwent neurological and MRI assessment including high-resolution T1, T2 and double inversion recovery sequences, diffusion- and susceptibility weighted imaging. We calculated the diffusion along perivascular space index, a proxy for glymphatic function, cortical and deep gray matter volume, white and cortical gray matter lesion volume and normal appearing white matter microstructural damage. Multiple sclerosis patients showed an overall lower diffusion along perivascular space index vs healthy controls (estimated mean difference: -0.09, P = 0.01). Both relapsing-remitting and progressive multiple sclerosis patients had lower diffusion along perivascular space index vs healthy controls (estimated mean difference: -0.06, P = 0.04 for relapsing-remitting and -0.19, P = 0.001 for progressive multiple sclerosis patients). Progressive multiple sclerosis patients showed lower diffusion along perivascular space index vs relapsing-remitting multiple sclerosis patients (estimated mean difference: -0.09, P = 0.03). In multiple sclerosis patients, lower diffusion along perivascular space index was associated with more severe clinical disability (r = -0.45, P = 0.001) and longer disease duration (r = -0.37, P = 0.002). Interestingly, we detected a negative association between diffusion along perivascular space index and disease duration in the first 4.13 years of the disease course (r = -0.38, P = 0.04) without any association thereafter (up to 34 years of disease duration). Lower diffusion along perivascular space index was associated with higher white (r = -0.36, P = 0.003) and cortical (r = -0.41, P = 0.001) lesion volume, more severe cortical (r = 0.30, P = 0.007) and deep (r = 0.42, P = 0.001) gray matter atrophy, reduced fractional anisotropy (r = 0.42, P = 0.001) and increased mean diffusivity (r = -0.45, P = 0.001) in the normal-appearing white matter. Our results suggest that the glymphatic system is impaired in multiple sclerosis, especially in progressive stages. Impaired glymphatic function was associated with measures of both demyelination and neurodegeneration and reflects a more severe clinical disability. These findings suggest that glymphatic impairment may be a pathological mechanism underpinning multiple sclerosis. The dynamic interplay with other pathological substrates of the disease deserves further investigation. Recent evidence has shown the existence of a CNS 'waste clearance' system, defined as the glymphatic system. Glymphatic abnormalities have been described in several neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Glymphatic function has not been thoroughly explored in multiple sclerosis, where neurodegenerative processes are intermingled with inflammatory processes. We aimed to investigate glymphatic system function in multiple sclerosis and to evaluate its association with clinical disability, disease course, demyelination and neurodegeneration, quantified using different MRI techniques. In this retrospective study, we enrolled 71 multiple sclerosis patients (49 relapsing-remitting and 22 progressive multiple sclerosis) and 32 age- and sex-matched healthy control subjects. All subjects underwent neurological and MRI assessment including high-resolution T1, T2 and double inversion recovery sequences, diffusion and susceptibility weighted imaging. We calculated the diffusion along perivascular space index, a proxy for glymphatic function, cortical and deep grey matter volume, white and cortical grey matter lesion volume and normal-appearing white matter microstructural damage. Multiple sclerosis patients showed an overall lower diffusion along perivascular space index versus healthy controls (estimated mean difference: -0.09, P = 0.01). Both relapsing-remitting and progressive multiple sclerosis patients had lower diffusion along perivascular space index versus healthy controls (estimated mean difference: -0.06, P = 0.04 for relapsing-remitting and -0.19, P = 0.001 for progressive multiple sclerosis patients). Progressive multiple sclerosis patients showed lower diffusion along perivascular space index versus relapsing-remitting multiple sclerosis patients (estimated mean difference: -0.09, P = 0.03). In multiple sclerosis patients, lower diffusion along perivascular space index was associated with more severe clinical disability (r = -0.45, P = 0.001) and longer disease duration (r = -0.37, P = 0.002). Interestingly, we detected a negative association between diffusion along perivascular space index and disease duration in the first 4.13 years of the disease course (r = -0.38, P = 0.04) without any association thereafter (up to 34 years of disease duration). Lower diffusion along perivascular space index was associated with higher white (r = -0.36, P = 0.003) and cortical (r = -0.41, P = 0.001) lesion volume, more severe cortical (r = 0.30, P = 0.007) and deep (r = 0.42, P = 0.001) grey matter atrophy, reduced fractional anisotropy (r = 0.42, P = 0.001) and increased mean diffusivity (r = -0.45, P = 0.001) in the normal-appearing white matter. Our results suggest that the glymphatic system is impaired in multiple sclerosis, especially in progressive stages. Impaired glymphatic function was associated with measures of both demyelination and neurodegeneration and reflects a more severe clinical disability. These findings suggest that glymphatic impairment may be a pathological mechanism underpinning multiple sclerosis. The dynamic interplay with other pathological substrates of the disease deserves further investigation.Recent evidence has shown the existence of a CNS 'waste clearance' system, defined as the glymphatic system. Glymphatic abnormalities have been described in several neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Glymphatic function has not been thoroughly explored in multiple sclerosis, where neurodegenerative processes are intermingled with inflammatory processes. We aimed to investigate glymphatic system function in multiple sclerosis and to evaluate its association with clinical disability, disease course, demyelination and neurodegeneration, quantified using different MRI techniques. In this retrospective study, we enrolled 71 multiple sclerosis patients (49 relapsing-remitting and 22 progressive multiple sclerosis) and 32 age- and sex-matched healthy control subjects. All subjects underwent neurological and MRI assessment including high-resolution T1, T2 and double inversion recovery sequences, diffusion and susceptibility weighted imaging. We calculated the diffusion along perivascular space index, a proxy for glymphatic function, cortical and deep grey matter volume, white and cortical grey matter lesion volume and normal-appearing white matter microstructural damage. Multiple sclerosis patients showed an overall lower diffusion along perivascular space index versus healthy controls (estimated mean difference: -0.09, P = 0.01). Both relapsing-remitting and progressive multiple sclerosis patients had lower diffusion along perivascular space index versus healthy controls (estimated mean difference: -0.06, P = 0.04 for relapsing-remitting and -0.19, P = 0.001 for progressive multiple sclerosis patients). Progressive multiple sclerosis patients showed lower diffusion along perivascular space index versus relapsing-remitting multiple sclerosis patients (estimated mean difference: -0.09, P = 0.03). In multiple sclerosis patients, lower diffusion along perivascular space index was associated with more severe clinical disability (r = -0.45, P = 0.001) and longer disease duration (r = -0.37, P = 0.002). Interestingly, we detected a negative association between diffusion along perivascular space index and disease duration in the first 4.13 years of the disease course (r = -0.38, P = 0.04) without any association thereafter (up to 34 years of disease duration). Lower diffusion along perivascular space index was associated with higher white (r = -0.36, P = 0.003) and cortical (r = -0.41, P = 0.001) lesion volume, more severe cortical (r = 0.30, P = 0.007) and deep (r = 0.42, P = 0.001) grey matter atrophy, reduced fractional anisotropy (r = 0.42, P = 0.001) and increased mean diffusivity (r = -0.45, P = 0.001) in the normal-appearing white matter. Our results suggest that the glymphatic system is impaired in multiple sclerosis, especially in progressive stages. Impaired glymphatic function was associated with measures of both demyelination and neurodegeneration and reflects a more severe clinical disability. These findings suggest that glymphatic impairment may be a pathological mechanism underpinning multiple sclerosis. The dynamic interplay with other pathological substrates of the disease deserves further investigation. |
| Author | Preziosa, Paolo Filippi, Massimo Carotenuto, Antonio Pagani, Elisabetta Cacciaguerra, Laura Rocca, Maria A |
| Author_xml | – sequence: 1 givenname: Antonio surname: Carotenuto fullname: Carotenuto, Antonio organization: Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy – sequence: 2 givenname: Laura surname: Cacciaguerra fullname: Cacciaguerra, Laura organization: Vita-Salute San Raffaele University, 20132, Milan, Italy – sequence: 3 givenname: Elisabetta surname: Pagani fullname: Pagani, Elisabetta organization: Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy – sequence: 4 givenname: Paolo orcidid: 0000-0002-7826-0019 surname: Preziosa fullname: Preziosa, Paolo organization: Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy – sequence: 5 givenname: Massimo orcidid: 0000-0002-5485-0479 surname: Filippi fullname: Filippi, Massimo organization: Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy – sequence: 6 givenname: Maria A orcidid: 0000-0003-2358-4320 surname: Rocca fullname: Rocca, Maria A organization: Vita-Salute San Raffaele University, 20132, Milan, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34919648$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAYhC1URD9gZEUeWUL9FbthQxUUpEosMKLodeJQI9sJsaMq_54CRWK6Z7g7nW6OJqENBqFLSm4oKfhS92DDEvagRS5O0IwKSTJGczn5x1M0j_GDECo4k2doykVBCylWM_S2caPvdpBsheMYk_HY-g5s701I2AbsB5ds5wyOlTN9G228xb1xh0Ab8N6mHf5ZgGvw8G4whBrXNoK2zqbxHJ024KK5OOoCvT7cv6wfs-3z5ml9t80qzlnKQCjaNFrUWkgpidGgCqqYLirWSAFQyQMSoQTkBYfVSoKuQdaGq4LwVa7YAl3_9nZ9-zmYmEpvY2Wcg2DaIZZMUiqlourbenW0Dtqbuux666Efy79L2BdZk2df |
| CitedBy_id | crossref_primary_10_1016_j_sleep_2024_10_019 crossref_primary_10_1002_epi4_12877 crossref_primary_10_1038_s41390_024_03655_w crossref_primary_10_1186_s10194_024_01726_1 crossref_primary_10_3348_kjr_2023_0360 crossref_primary_10_1016_j_jad_2024_08_094 crossref_primary_10_1007_s00018_023_05073_3 crossref_primary_10_3390_brainsci14010036 crossref_primary_10_1007_s00234_023_03240_8 crossref_primary_10_1111_head_14607 crossref_primary_10_1016_j_nbd_2024_106560 crossref_primary_10_33590_emjneurol_HRFB2147 crossref_primary_10_1002_alz_13789 crossref_primary_10_3390_jcm12206646 crossref_primary_10_4103_1673_5374_391312 crossref_primary_10_1016_j_msard_2023_105141 crossref_primary_10_3389_fnins_2023_1214652 crossref_primary_10_1007_s11055_024_01585_y crossref_primary_10_1002_brb3_3042 crossref_primary_10_1016_j_autrev_2025_103902 crossref_primary_10_1093_brain_awae251 crossref_primary_10_1007_s00234_023_03270_2 crossref_primary_10_3389_fneur_2023_1232304 crossref_primary_10_1002_jmri_28797 crossref_primary_10_1148_radiol_221512 crossref_primary_10_1007_s44258_024_00021_7 crossref_primary_10_1007_s11055_024_01604_y crossref_primary_10_2174_0118744400389049250723091323 crossref_primary_10_1016_j_nicl_2025_103769 crossref_primary_10_37489_2949_1924_0086 crossref_primary_10_1007_s00415_024_12525_8 crossref_primary_10_1186_s13195_024_01407_w crossref_primary_10_1016_j_acra_2024_11_010 crossref_primary_10_3389_fnagi_2022_974114 crossref_primary_10_1093_brain_awad274 crossref_primary_10_1007_s11604_022_01275_0 crossref_primary_10_1016_j_bbiosy_2025_100117 crossref_primary_10_1093_braincomms_fcaf252 crossref_primary_10_1016_j_jns_2024_122884 crossref_primary_10_1186_s12987_023_00429_0 crossref_primary_10_1016_j_nbd_2024_106426 crossref_primary_10_3389_fneur_2022_843883 crossref_primary_10_1002_advs_202401039 crossref_primary_10_1016_j_jchemneu_2023_102357 crossref_primary_10_1002_mdc3_70296 crossref_primary_10_1111_ene_16521 crossref_primary_10_1016_j_heliyon_2025_e43451 crossref_primary_10_1016_j_neurad_2023_10_009 crossref_primary_10_1016_j_neuroscience_2025_06_028 crossref_primary_10_1016_j_jpsychires_2025_02_045 crossref_primary_10_1016_j_mri_2025_110319 crossref_primary_10_1111_head_14514 crossref_primary_10_1002_alz_14453 crossref_primary_10_1002_hbm_70334 crossref_primary_10_1016_j_heliyon_2025_e42085 crossref_primary_10_3390_ijms26030884 crossref_primary_10_1016_j_msard_2025_106531 crossref_primary_10_3389_fnagi_2022_916633 crossref_primary_10_1016_j_brainresbull_2025_111232 crossref_primary_10_1016_j_msard_2024_105437 crossref_primary_10_1007_s00415_023_11649_7 crossref_primary_10_1016_j_mrl_2024_200154 crossref_primary_10_3389_fneur_2025_1543725 crossref_primary_10_1177_13524585251364720 crossref_primary_10_1016_j_msard_2023_105136 crossref_primary_10_1097_j_pain_0000000000002979 crossref_primary_10_2147_MDER_S480815 crossref_primary_10_1111_ejn_70105 crossref_primary_10_1097_WCO_0000000000001360 crossref_primary_10_3389_fnins_2022_863117 crossref_primary_10_1007_s00406_025_02037_5 crossref_primary_10_1016_j_msard_2024_105550 crossref_primary_10_1016_j_sleep_2024_01_028 crossref_primary_10_3233_JAD_231131 crossref_primary_10_1016_j_tjpad_2025_100156 crossref_primary_10_1111_bpa_13263 crossref_primary_10_1002_hbm_70282 crossref_primary_10_1016_j_neulet_2024_137737 crossref_primary_10_1007_s11910_023_01293_z crossref_primary_10_1038_s41526_024_00365_9 crossref_primary_10_1002_hbm_26680 crossref_primary_10_1038_s41380_024_02778_0 crossref_primary_10_1186_s13195_024_01484_x crossref_primary_10_3389_fimmu_2024_1380063 crossref_primary_10_1016_j_arr_2023_101885 crossref_primary_10_1111_jon_70086 crossref_primary_10_1177_11795735241259429 crossref_primary_10_3390_cells13161316 crossref_primary_10_1093_rheumatology_keae251 crossref_primary_10_1136_svn_2022_002191 crossref_primary_10_1007_s10072_025_08275_8 crossref_primary_10_1007_s40120_025_00823_w crossref_primary_10_1002_adtp_202400088 crossref_primary_10_1038_s41531_025_00909_0 crossref_primary_10_1002_ana_26911 crossref_primary_10_1002_ana_26516 crossref_primary_10_1016_j_msard_2025_106447 crossref_primary_10_1007_s10334_025_01248_0 crossref_primary_10_1016_j_msard_2024_105456 crossref_primary_10_1016_j_seizure_2024_06_021 crossref_primary_10_1177_0271678X231194863 crossref_primary_10_1007_s00234_023_03269_9 crossref_primary_10_1007_s12975_024_01250_z crossref_primary_10_1007_s00330_025_11359_w crossref_primary_10_1093_sleep_zsae251 crossref_primary_10_3389_fnagi_2023_1173221 crossref_primary_10_3389_fneur_2023_1143646 crossref_primary_10_1007_s00415_022_11381_8 crossref_primary_10_1159_000542902 crossref_primary_10_3389_fneur_2023_1173779 crossref_primary_10_1016_j_bpsc_2025_09_002 crossref_primary_10_1155_ane_8858684 crossref_primary_10_17116_jnevro202312310142 crossref_primary_10_1002_nbm_5200 crossref_primary_10_1007_s00330_023_09473_8 crossref_primary_10_3390_brainsci15070766 crossref_primary_10_1007_s00234_022_03018_4 crossref_primary_10_7717_peerj_16465 crossref_primary_10_1016_j_mehy_2025_111736 crossref_primary_10_1186_s13195_025_01707_9 crossref_primary_10_1016_j_mric_2024_01_002 crossref_primary_10_3389_fnins_2025_1545885 crossref_primary_10_1007_s00330_023_10220_2 crossref_primary_10_1016_j_nbd_2022_105986 crossref_primary_10_1016_j_parkreldis_2024_107089 crossref_primary_10_1016_j_msard_2024_105878 crossref_primary_10_3389_fpsyt_2025_1509093 crossref_primary_10_1002_brb3_70672 crossref_primary_10_1016_j_neuron_2025_04_027 crossref_primary_10_1111_cen3_70015 crossref_primary_10_1007_s00330_023_10122_3 crossref_primary_10_1097_RLI_0000000000001120 crossref_primary_10_1002_ana_26419 crossref_primary_10_1177_13524585241280842 crossref_primary_10_3390_diagnostics14171993 crossref_primary_10_2147_JIR_S532401 crossref_primary_10_1016_j_ebiom_2023_104708 crossref_primary_10_1186_s10194_023_01673_3 crossref_primary_10_1016_j_mri_2025_110484 crossref_primary_10_1073_pnas_2426192122 crossref_primary_10_1007_s10571_025_01598_2 crossref_primary_10_1146_annurev_neuro_091922_031205 crossref_primary_10_1080_19490976_2024_2387800 crossref_primary_10_1227_neu_0000000000003050 crossref_primary_10_1016_j_acra_2024_11_030 crossref_primary_10_1016_j_pediatrneurol_2024_01_026 crossref_primary_10_3389_fnagi_2023_1179988 crossref_primary_10_1016_j_neuroscience_2025_03_044 crossref_primary_10_1080_14737175_2024_2304116 crossref_primary_10_1212_NXI_0000000000200414 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| DBID | NPM 7X8 |
| DOI | 10.1093/brain/awab454 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| ExternalDocumentID | 34919648 |
| Genre | Journal Article |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 0R~ 1TH 23N 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAIMJ AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAVLN AAWTL ABDFA ABEJV ABEUO ABGNP ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNHQ ABNKS ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFS ACIWK ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AELWJ AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM C45 CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH NPM O9- OAUYM OAWHX OBOKY OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 RIG ROL ROX RUSNO RW1 RXO TCURE TEORI TJX TLC TR2 VVN W8F WH7 WOQ X7H YAYTL YKOAZ YSK YXANX ZKX ~91 7X8 ABPQP ABXZS ADNBA AEMQT AFYAG AHGBF AJBYB AJNCP ALXQX |
| ID | FETCH-LOGICAL-c332t-a471ffb4db46660eba79172b9c2f64aac6b9c0474a593a886abda6de379038572 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 174 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000824358400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2156 |
| IngestDate | Wed Oct 01 13:32:21 EDT 2025 Wed Feb 19 02:27:25 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | neurodegeneration progression pathology glymphatic system multiple sclerosis |
| Language | English |
| License | The Author(s) 2021. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c332t-a471ffb4db46660eba79172b9c2f64aac6b9c0474a593a886abda6de379038572 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-7826-0019 0000-0002-5485-0479 0000-0003-2358-4320 |
| OpenAccessLink | https://academic.oup.com/brain/article-pdf/145/8/2785/45599745/awab454.pdf |
| PMID | 34919648 |
| PQID | 2611667177 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2611667177 pubmed_primary_34919648 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-08-27 |
| PublicationDateYYYYMMDD | 2022-08-27 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-27 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationTitleAlternate | Brain |
| PublicationYear | 2022 |
| SSID | ssj0014326 |
| Score | 2.6895986 |
| Snippet | Recent evidences showed the existence of a central nervous system 'waste clearance' system, defined as glymphatic system. Glymphatic abnormalities have been... Recent evidence has shown the existence of a CNS 'waste clearance' system, defined as the glymphatic system. Glymphatic abnormalities have been described in... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2785 |
| Title | Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34919648 https://www.proquest.com/docview/2611667177 |
| Volume | 145 |
| WOSCitedRecordID | wos000824358400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qRLz4_TG_iOA1bG3SpPEiIk4PbuygsouUpEmgoN1cp7L_3pc2w5MgeGl7CbTpy3vv9z5-D6GLiFqbGu5IrjkAlNxFRMcqIlIyznTiJK259J4fxGCQjkZyGAJuVSirXOjEWlGbce5j5B3w9CPOAXyIq8k78VOjfHY1jNBYRi0KroyXajH6ySIwGofuoi4B08YDxyaA-I72Axg66ktp5icB_OZd1lamt_nf99tCG8G_xNeNQGyjJVvuoLV-yKDvope71zn8QM_TihsWZ-wbJYupjxLiosSLCkNcwXowoUV1iaehYg77qC2uPwob9QaqCKvSYBN4emfzPfTUu328uSdhxALJKY1nRIFtck4zoxngmK7VSgB-i7XMY8eZUjmHxy4TTCWSqjTlShvFjaVC-pSiiPfRSjku7SHClDtPbmhpxOGeSJVaQKgmjYXlxrikjc4XG5eBCPu8hCrt-KPKfraujQ6a3c8mDddGBqLiKcPSoz-sPkbrsW9O6MLZFyeo5eAA21O0mn_Oimp6VssGXAfD_jc138Yc |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glymphatic+system+impairment+in+multiple+sclerosis%3A+relation+with+brain+damage+and+disability&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Carotenuto%2C+Antonio&rft.au=Cacciaguerra%2C+Laura&rft.au=Pagani%2C+Elisabetta&rft.au=Preziosa%2C+Paolo&rft.date=2022-08-27&rft.issn=1460-2156&rft.eissn=1460-2156&rft.volume=145&rft.issue=8&rft.spage=2785&rft_id=info:doi/10.1093%2Fbrain%2Fawab454&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2156&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2156&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2156&client=summon |